Mohamad Hussein
Direttore/Membro del Consiglio presso ChemioCare, Inc.
Profilo
Mohamad Hussein has worked as a Director at ChemioCare, Inc. and Starton Therapeutics, Inc.
Posizioni attive di Mohamad Hussein
| Società | Posizione | Inizio |
|---|---|---|
ChemioCare, Inc.
 ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - |
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | Health Technology |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
- Borsa valori
- Insiders
- Mohamad Hussein
